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In February 2014, a consortium of scientists convened as part of the University of California Davis 
Cardiovascular Symposium to bring together experimental and mathematical modeling perspectives 
and discuss points of consensus and controversy on the topic of sodium in the heart 1. This paper 
summarizes the topics of presentation and discussion from the Symposium, with a focus on aberrant 
sodium channels and abnormal sodium homeostasis in cardiac arrhythmias and therapy from cell to the 
whole heart.   
 
DISRUPTION OF SODIUM HOMEOSTASIS IN CARDIAC DISEASE 
 
Although normal cycling of intracellular Ca2 + in cardiac myocytes is often considered a critical 
indicator of mechanical functioning in the heart, the intracellular Na+ concentration ([Na+]i) is tightly 
coupled to Ca2 + homeostasis and is an increasingly recognized modulating force of cellular 
excitability, frequency adaptation and cardiac contractility 2 3 4. The direct coupling between 
intracellular Na+ and Ca2 +concentrations is mediated via the Na+/Ca2 + exchanger (NCX), which 
exchanges 3 Na+ for each Ca2 +, and comprises the primary cellular extrusion mechanism for Ca2 +. The 
NCX can operate in both forward mode, during which it extrudes Ca2 +, or may promote Ca2 + influx 
when it operates in the ‘reverse mode’”.  The activity of NCX is sensitively tuned to changes in [Na+]i., 
so that a millimolar increase in the concentration of Na+i, resulting from increases in heart rate, 
sympathetic tone or disease can result in changes to NCX activity that alter Ca2 + homeostasis leading 
to intracellular Ca2 + loading in both cellular and sarcoplasmic reticulum (SR) compartments 5.   The 
consequence of intracellular cardiac myocyte Ca2 + loading is stronger contraction 6, but if too much 
Ca2 + loading occurs, as in pathological states, there is potential for increased leak from the higher SR 
Ca2 + load, which can result in spontaneous Ca2 + waves.    If the Ca2 + waves are sufficiently large or 
persistent, the excess intracellular Ca2 + will be extruded via the NCX resulting in depolarizing current 
that may bring the cell to threshold Na channel activation, casing delayed afterdepolarizations (DADs) 
and arrhythmogenic triggered action potentials. For more detailed description of structural and 
functional determinants of NCX, please refer the white paper #3 (REF). 
 
An additional important cellular mechanism for maintenance of [Na+]i. homeostasis is the sodium-
potassium ATPase (NKA), which uses energy derived from hydrolysis of an ATP molecule, allowing 
extrusion of three Na+ ions in exchange for two K+ ions.   The NKA is half-maximally activated 
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between 10 – 22 mM [Na+]i and 1 – 2 mM external K+ , respectively 7. Thus, at 4 mM normal 
extracellular K+, NKA is ~ 70% saturated, with plenty of available ATP (5–10 mM) (half-maximal 
NKA activation is 80–150 μM) 8. The NKA is covered in detail in white paper #3 (REF). 
 
Cardiac myocytes also contain Na transport mechanisms that promote simultaneous maintenance of 
[Na+]i. homeostasis and physiological pH including the sodium-hydrogen exchanger (NHE), which 
moves sodium into the cell in exchange for proton export 9.    The sodium-bicarbonate symporter 
(NBC) is also present in myocytes and acts as an additional mechanism to couple [Na+]i. homeostasis 
and pH 9.  In disease states, the importance of the coupling between multiple Na homeostatic 
mechanisms is evident.   In ischemia, failure of ion homeostasis starts with an influx of Na+ through 
the Na+/H+ exchanger (NHE) 10 in attempt to raise the acidified pH (through the extrusion of H+). In 
ischemia/reperfusion injury, activation of the N a+/H+ exchanger (NHE) and Na+/HCO3− cotransporter 
(NBC), a pathological increase in the persistent late Na current component, Na+ entry through 
connexin hemichannels, and NKA inhibition results in reverse mode NCX activity that leads to Ca2 + 
overload 2.    During hypoxia, NHE from rabbit ventricular myocytes stimulated at 1 Hz accounted for 
39% of the total Na+ influx (as compared to 5% during normoxia) 11. Inhibition of the NHE during 
ischemic episodes attenuated the rise in intracellular Na+ 12,13.  Along with Na+ influx via the NHE, a 
parallel decrease in energy production due to mitochondrial dysfunction and loss of ATP results in 
reduced Na+ elimination through the Na+/K+ ATPase 14, which further augments intracellular Na+. 
 
Another key disease state marked by sodium dysregulation is heart failure (HF), where it has been 
shown that [Na+]i is elevated in humans and in numerous animal models 15 6 16 17 and 18.   Elevation of 
[Na+]i in HF may represent a compensatory adaptation that allows for an increase in Ca2 + influx via 
NCX, leading to improved contraction, as a type of physiological “digitalis”.  
 
While it is generally agreed upon that [Na+]i. is increased in many forms of heart dicecsease disease, 
the specific pathways responsible for Na elevation are still a matter of controversy.  Increased Na entry 
through Na channels and Na/H exchanger and reduced Na/K pump activity have been found in various 
animal models of disease. It could well be that the specific pathway is both species and model-
dependent.  For example, NKA expression is reduced in failing human myocardium 19, although 
mRNA levels are unchanged 20. In the rat, mRNA and protein levels of the primary NKA-α1 isoform 
are preserved in most HF models, whereas the protein levels of NKA-α2 are apparently reduced, 
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while NKA-α3 is increased 21. In rabbit HF models all NKA isoforms have been shown to exhibit 
reduced protein expression in myocytes 22. Clearly, a direct causative link between biochemical 
changes and function cannot be made because of potential confounding factors such as altered protein 
regulation, function or activity that are not measured with biochemical assays.   An example is the 
differential regulation of NKA in HF, described in detail in White Paper #3 (REF).   
 
Figure 1:  Schematic depiction of Na+ transport processes in the cardiac myocyte.  From 2. 
 
Larger Na+ influx by other mechanisms has also been proposed to increase [Na+]i in HF.   For example, 
a TTX sensitive diastolic Na influx was observed to be upregulated in rabbits with pressure and 
volume-overload induced HF 15.   NHE upregulation has also been documented in HF 16.    Na+ influx 
also occurs as a result of a gain of function of the Na+ channel in the form of the non-inactivating late 
component of the Na+current (INaL) that will be detailed in the following sections.    
 
Elevated [Na+]i is linked to disruptions in cardiac energetics and metabolism  
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Although increased [Na+]i may improve the contractile function of the diseased heart, elevated [Na+]i 
may have a pathological impact on cardiac metabolism and oxidative state.  For example, the increase 
in [Na+]i and reverse mode NCX mediated Ca2 + influx during the cardiac action potential is 
energetically less efficient than normal SR Ca2+ release and may contribute to a mismatch between 
energy supply and demand in the failing heart. 23.   Furthermore, it has been shown that when 
intracellular Ca2 + transients were triggered by NCX mediated Ca2 + entry, the efficiency of 
mitochondrial Ca2 + uptake was substantially reduced, suggesting reduced efficiency in the transport 
mechanism necessary to drive Ca2 +-induced stimulation of Krebs cycle processes 24.  An interesting 
point to consider and that needs to be clarified is whether this mitochondrial calcium uptake is rapid 
enough to track changes in intracellular sodium and calcium during systole and diastole.  
 
In failing cardiac myocytes, increased [Na+]i impairs energy supply-and-demand matching by 
promoting acceleration of mitochondrial Ca2 + efflux, via the mitochondrial Na+/Ca2 + exchanger 
(NCLX), which extrudes Ca2 +from the mitochondria in exchange for Na+ 25.  Increases in [Na+]i have 
also been shown to cause an increase in mitochondrial H2O2 formation in normal and failing cardiac 
myocytes 26 that may additionally aggravate the Na+-induced depletion of the antioxidative capacity 
and exacerbate oxidative stress in the failing heart 25. 
 
ABERRATIONS IN SODIUM CHANNEL FUNCTION IN CARDIAC DISEASE 
 
In addition to changes in [Na+]i homeostatic mechanisms in the heart, changes to the distribution and 
function of cardiac Na channels have been linked to disease manifestation and progression in inherited 
and acquired cardiac arrhythmias.   Either gain- and loss-of-function results, depending on the disease 
state, and both disruptions can result in dangerous proarrhythmic consequences arising from alterations 
in cardiac conduction and repolarization.  
 
Loss of Na channel function 
In the case of loss of Na channel function, either a result of disease-induced remodeling or as a result 
of drug application, reduced Na current can lead to insufficient cellular excitability to allow 
propagation of electrical waves, leading to a well-known precursor to reentrant arrhythmias - 
conduction block.  
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One instance of remodeling of Na channels that may play a critical role in arrhythmogenesis is in the 
infarct border zone where the electrical substrate is extensively remodeled compared to normal non-
infarcted epicardium.   The fact that progressive electrical remodeling that occurs in chronic disease 
states has been identified as a biomarker for sudden cardiac death, indicates the critical importance of 
revealing its mechanisms 27 28.   Na+ currents (as well as Ca2+, and K+ currents) in cells isolated from 
the epicardial border zone (EBZ) of 5-day infarcted hearts have been shown to have both altered 
current amplitudes and changes in kinetics 29 30 31 32.   Within the reentrant circuit, two distinct cell 
regions have been identified, cells from the central common pathway of the circuit (IZc), and cells 
from the outer pathway on the other side of the line of block (outer pathway, IZo) 33. Cells from both 
regions of the infarct zone regions had reduced Na+ current density, but the cells from the IZo also 
exhibited slower Na+ channel kinetics for time to peak and current decay 29. These changes in Na 
channel function along with some observed changes to L-type Ca2+ currents give rise to electrical 
anisotropy that promotes stable lines of block within the zone 34.  These stable lines of block then 
allow for development of sustained reentrant excitation and stable ventricular tachycardias (VTs) in the 
epicardial border zone (EBZ).  
 
If regional differences of ionic currents in cells of the EBZ are the mechanisms underlying the lines of 
block observed in the EBZ, then restoration of either the Na+ channel or the L-type Ca2+ channel 
should be antiarrhythmic by disrupting the stability of the lines of block leading to termination of 
reentry.  Indeed, recent studies 35 suggest that gene transfer mediated overexpression of the skeletal 
muscle sodium channel (SkM1), resulted in improved Na channel availability since SkM1 channels 
have positively shifted kinetics of inactivation rendering them primarily open at depolarized potentials 
at which cardiac Na channels are closed. SkM1 overexpression improved conduction and reduced the 
incidence of inducible VT/VF post-myocardial infarction 36.  Such approaches constitute the potential 
for new development of strategic interventions to restore electrical disruptions in the heart arising from 
electrically based remodeling.  
 
Gain of Na channel function 
Many recent works have focused on gain-of-function of the Na+ current since a range of cardiac 
diseases are marked by pathological increases in the persistent late Na current component (late Na 
current, INaL) that follows the rapid transient activation of INa.   INaL is upregulated in many pathologic 
conditions, such as in the failing and/or ischemic heart, in the heart exposed to oxidative stress, and in 
hearts of patients with congenital long QT3 syndromes 37 38 39 40 41 42 43. 37-43  Ca2+ dysregulation 
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results in pathological effects to promote late INa (INaL) 44,45 via activation of CaMKII 46, increased 
mitochondrial oxidative phosphorylation 47 and consequent increased ROS 47,48.  Please see White 
Paper #2  (REF) for detailed coverage of Na channel regulation.   Increased INaL leads to action 
potential prolongation, disruption of normal cellular repolarization, development of arrhythmia 
triggers, and propensity to ventricular arrhythmia.  In heart failure, pharmacological targeting of INaL 
has been shown to result in: 1) normalization of repolarization; 2) decrease in beat-to-beat APD 
variability; and 3) improvement in Ca2 + handling and contractility 49-52.  
 
At least three distinct alterations in NaV1.5 gating have been shown to increase in INaL including 
window currents, differential gating modalities, and non-equilibrium gating. These mechanisms were 
initially revealed via detailed electrophysiological study of mutations in SCN5A that resulted in Long 
QT Type 3 Syndrome in patients.   Window current describes the Na current that is measurable in the 
voltage range where the steady state inactivation curve and activation curve overlap 53-55. The current 
can be observed within the “window” of voltage during cardiac repolarization or as a steady-state 
equilibrium current during voltage clamp.   The window can be affected by changes to the activation 
and inactivation gating that result in expansion of the voltage range.  In addition to mutations and 
polymorphisms, there have been a slew of physiological modulators identified such as Ca2 +, 
calmodulin, and phosphorylation (discussed in White Paper #2) that in normal physiology and in 
pathological conditions increase the size of the window 54.   
 
The bursting of Na channels is a well-described gating mode where channels undergo a transient 
failure of channel inactivation. Maltsev and Undrovinas recorded INaL from heterologously expressed 
NaV1.5 in the absence of other isoforms 40, showing that bursting channels were indeed of the same 
form as those underlying the transient inward current.   Clancy et al. recorded and modeled the 
transitions from normally inactivating Na+ channels to bursting channels in heterologously expressed 
single NaV1.5 sodium channels. A computational model based on these rates was then used to predict 
the magnitude and rate dependence of INaL expected from ensemble currents 56. 
 
Non-equilibrium gating describes another form of INaL that is not observed during typical voltage 
clamp depolarization protocols 57.  However, in response to a negative ramp current, a transient inward 
current is observed.  The amplitude of the current if sensitively dependent on the rate of recovery from 
inactivation, where faster recovery or a shift in the voltage dependence of recovery from inactivation 
promotes the current.   Just as for the window current, non-equlibrium Na current is affected by a 
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number of physiological modulators including calmodulin and phosphorylation (discussed in White 
Paper #2). 
 
Intrinsic gating abnormalities of the cardiac Na+ channel, were reported by Maltsev and Undrovinas in 
their description of a novel, ultraslow inactivating Na current, INaL, in both normal and failing human 
hearts 39.  The same group also showed an increased density and slower inactivation kinetics of INaL58 
in chronic heart failure as compared to normal hearts. In single channels two modes of gating 
underlying late INa were observed, late scattered mode gating and burst mode of gating that had slower 
kinetics in failing human ventricular myocytes compared to normal ventricular myocytes 40. 
Importantly, there were no differences in the unitary conductance of late Na+ current between normal 
and failing human hearts, suggesting a single population of channels that are upregulated in HF 59. 
 
LINKING Na+ AND Na+ CHANNEL ABNORMALITIES TO ARRHYTHMIAS 
 
Disruptions in Na based processes in the heart foster arrhythmias by multiple mechanisms, depending 
on the specific perturbation to the Na+-linked process.  Of major benefit to revealing and understanding 
the mechanisms of Na based arrhythmias is the development of numerous new experimental 
techniques including examples such as targeted subcellular imaging 60-63, SR Ca2+ imaging 64, advances 
in electrophysiology 65, “cell-in-gel” and other techniques for mechanotransduction 66 67, mitochondrial 
imaging 68, stem cell technologies 69, just to name a few.   
 
 
In addition to the developments in experimental techniques, there have been dramatic gains in 
accessibility of modern computing power, computational speed and reduction in computing cost. 
Recent advances have also been made in numerical techniques and computing 70,71 72,73 70-73, the 
implementation of customizable solvers such as Continuity 74, modeling platforms like CHASTE and 
OpenCMISS 75,76, and infrastructures aimed at facilitating standardization, interoperability and 
dissemination of models (e.g CellML and FieldML) 75 76 77 78 79 75-79.  
 
Mathematical models of cardiac physiology are widely used to complement experimental findings and 
clinical observations to improve understanding of cardiac electrical function in health and disease.  
Implementation of such models offers multiple advantages, especially that they enable exploration of 
high dimensional models to determine how their range of dynamical behaviors corresponds to that of 
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low dimensional models.  Emergent behaviors can be mapped back to underlying parameters through 
component dissection, to reveal mechanisms of emergent behaviors, a function for which there is no 
efficient comparable experimental counterpart.   
 
Experimental approaches and computational modeling and simulation are complementary methods to 
determine how abnormalities in Na processes at the level of the cell can cause emergent arrhythmias in 
the whole heart.   An example is a hallmark arrhythmia trigger in human heart failure resulting from 
Ca2+-induced delayed afterdepolarizations (DADs).  When Na+ accumulation and overload occurs in 
cells, DADs arise because the resulting cytosolic Ca2 + accumulation via reverse-mode NCX may 
ultimately exceed Ca2 + efflux and precipitate Ca2 + overload. A pathological version of the Ca2 +-
induced-Ca2 + release ensues, whereby spontaneous SR Ca2 + release leading to overloaded intracellular 
Ca2 + that is extruded by NCX, which may depolarize the cell sufficiently to activate Na channels 
leading to the emergence of delayed afterdepolarizations (DADs) and, if large enough, arrhythmogenic 
triggered action potentials.  Because Na+ mediated Ca2 + overload does not occur uniformly in time or 
space, beat-to-beat variability in repolarization and emergent triggering early afterdepolarizations 
(EADs) and DADs occur unpredictably.  
 
DADs occurring in a single myocyte are an insufficient source of current to trigger a premature beat in 
the whole heart because the current generated in single cell is not enough to overcome the large 
electrotonically coupled downstream sink of tissue. Mathematical models have shown that DADs must 
occur simultaneously in many cells in order to generate an arrhythmia trigger 80.   
 
In the case of loss of Na channel function as described in infarct border zone, a reduction in 
excitability at the cellular level emerges in coupled tissue as slowing of conduction velocity of the 
propagating depolarizing wave that drives cardiac excitation.   Slow conduction can result in an 
increase in the “vulnerable window” to unidirectional block and, if the conditions are favorable, 
retrograde conduction, promoting reentrant arrhythmia in the organ 81, 82 81-83 84 85,86 .   It is important to 
note that slow conduction is enough to prolong action potential duration (APD) at the cellular level and 
QT interval at the organ level as a result of the intrinsic dynamical properties of Na channels that give 
rise to the restitution relationship.  The restitution relationship describes the correlation between APD 
and the preceding diastolic interval (DI).   As the DI increases as a result of slow conduction, the 
subsequent AP will be relatively prolonged.  If the DiI is sufficiently long and other anomalies are 
present, reductions in repolarization reserve occur and even triggered arrhythmias such as early 
Formázott: Nincs aláhúzás
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afterdepolarizations (EADs) may emerge 87 88 49 53 89.   Conversely, when the DI is very short, such as 
during rapid pacing or tachycardia and combined with other perturbations such as drugs or disease, the 
relationship between APD and DI may be very steep.  In this situation, arrhythmogenic oscillation of 
the APD termed alternans can develop.  All of these disruptions to normal cardiac electrical activity Hi 
promote development of reentrant arrhythmias and wavebreak causing fibrillation90.  
 
A gain of function of the Na channel during disease that results in an increase Llate Na+ current has 
also been linked to arrhythmias associated with acquired diseases such as heart failure and post MI 
remodeling, due to their impact on action potential duration and repolarization abnormalities. 
Approximately 40% of chronic heart failure patients die due to sudden cardiac death, with ventricular 
tachycardia and fibrillation documented in 80% of patients 49,91,92. Conditions and diseases that lead to 
an increased late INa exhibit electrical instability (due to afterdepolarizations, beat-to-beat variability in 
repolarization, ventricular arrhythmias), mechanical instability (impaired diastolic relaxation and 
ventricular wall tension, increased diastolic and decreased systolic force generation), as well as 
mitochondrial dysfunction 47. This sets up a cascade leading to further ischemia and abnormal 
contraction in a pathological feedback loop.  Failing canine ventricular myocytes with prolonged APs, 
Ca2 + transients and substantial diastolic Ca2 + accumulation leading to spontaneous Ca2 + release were 
shown to improve with TTX and ranolazine (a selective INaL blocker) 93-95. These results are additional 
strong indication of the link between pathological INaL to the induction of deranged Ca+ homeostasis at 
the cellular level. A subsequent study using human ventricular myocytes 39 similarly found 
improvement with TTX. 
 
NEW THERAPEUTIC APPROACHES FOR NA LINKED ARRHYTHMIAS 
 
As described above, both gain- and loss-of-function in the cardiac Na channel can result in dangerous 
proarrhythmic consequences by altering cardiac conduction and repolarization.   Thus, the prospect of 
targeted pharmacological treatment to modify Na+ based arrhythmias has fueled historical and recent 
pursuit of new drugs.   However, the history of antiarrhythmic drug failures makes careful and reliable 
assessment of drug effects on cardiac rhythms a preclinical necessity to ensure safety and efficacy.  
 
The difficulty in predicting drug effects on the electrical activity of the heart is clear from both the 
failure of large clinical trials to demonstrate drug safety for multiple antiarrhythmic drug classes (for 
example, the CAST 96 and SWORD 97 clinical trials), and from the market withdrawal of otherwise 
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promising drugs for treating cardiac dysrhythm, psychiatric disorders, gastrointestinal symptoms and 
infection following unexpected sudden cardiac death 98.    These events have resulted in a burdensome 
regulatory process for preclinical drugs that have prevented emergence of potentially therapeutic 
agents for clinical use.     
 
The reasons that it has been so difficult to predict ion channel targeting drug effects on cardiac 
electrical activity are that most antiarrhythmic drugs have complex interactions with multiple channels, 
conformational state specificity, bioactive metabolites and neutral and charged drug fractions. Drugs 
alter the action potential waveform, which in turn affects drug potency.   Thus, it is extremely difficult 
to know how intended antiarrhythmic drugs that primarily target ion channels will alter emergent 
electrical activity in the whole heart.    Recently, the FDA and other stakeholders have suggested the 
potential implementation of a new paradigm for cardiotoxicity testing that includes implementation of 
complementary developments in computational modeling and simulation approaches and stem cell 
technologies 99.    
 
Modeling and simulations for predictive pharmacology 
 
Cardiac modeling and simulation has recently been utilized to investigate mechanisms of Na+ channel 
blocking drugs that both reduce peak Na+ current and that specifically target the late Na+ current.   A 
recent study by Cardona et al. investigated lidocaine effects in a multiscale computational model100.   
The authors demonstrated both anti-fibrillatory effects in normal tissue and predicted the potential for 
proarrhythmia with lidocaine during pathologies including acidosis and ischemia.   
 
Moreno et al. 84 also implemented modeling and simulation approaches to investigate the mechanisms 
of failure of the once promising antiarrhythmic drug flecainide, the subject of the cardiac arrhythmia 
suppression trial (CAST), which, in the clinical trial startlingly showed increased mortality with 
flecainide over placebo.   In the computational modeling and simulation study, the dynamical 
complexity of the drug kinetics was modeled for both charged and neutral drug fractions.  After 
developing the drug-channel model, a simulation in cells first confirmed experimental findings:  no 
overt proarrhythmic potential was ever observed at the cellular level 84.  In tissue level simulations, the 
outcome was dramatically different.   Substantial use-dependent block by flecainide (an intrinsic 
dynamical property of channel block) was predicted in the model to result in failed impulse 
conduction, a higher dimensional phenomenon that emerged as a result of increased electrotonic load 
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in coupled tissue.  Proarrhythmic conduction block led to development of tachycardia indicated by 
spiral wave reentry, which was verified experimentally 84.  This emergent phenomenon was linked 
back to the fundamental mechanism - the drug kinetics of unblock, identified as the basic mechanism 
of failure.   Moreover, the study indicated that the kinetics of drug interactions for lidocaine promoted 
safety in higher dimensions as indicated by no reentrant arrhythmias in the presence of lidocaine in 
normal tissue.  
 
Disease induced enhancement of late INa promotes the development of arrhythmogenic after-
depolarizations, triggered arrhythmic activity, and torsades de pointes (TdP) in cardiac ventricular 
myocytes, cardiac tissue, and intact hearts 87 88 101 102 103. Pharmacological targeting of INaL has been 
shown to improve cardiac electrical function in myocytes challenged by cardiac glycosides, hydrogen 
peroxide, pharmacological enhancement of late INa, and even with drugs that block hERG (IKr) and 
reduce repolarization reserve 104 105 106 88 101 41 102 42 49 107.   
 
Recently, modeling and simulation have been used to probe and predict effects of the selective INaL 
inhibitor ranolazine in pathological situations 108.  Simulations of clinically relevant concentrations of 
drug were used to predict the cellular level effects of Na+ channel blockade using both ranolazine and 
its active metabolites on hERG, which have potent blocking effects in the therapeutically relevant 
range.  The model was used to predict if therapeutic effects of targeted pharmacological treatment by 
ranolazine prevailed over the unintended pathological block of hERG for normalizing arrhythmia 
triggers (EADs) in bradycardia-dependent arrhythmias in LQT3, as well tachyarrhythmogenic triggers 
arising from heart-failure induced remodeling (e.g. DADs).   Model predictions suggested that acute 
targeting of late INa with ranolazine can be an effective therapeutic strategy in diverse arrhythmia 
provoking situations that arise from a common pathway of increased pathologic late INa.  
 
Trenor et al. developed a tool for in-silico preclinical anti-arrhythmic drug safety assessment, that 
predicted the impact of IKr/INaL ratio of steady-state block of drug candidates on “torsadogenic” 
biomarkers that they defined as AP duration, triangulation, reverse rate-dependence, transmural 
dispersion of repolarization and electrocardiogram QT interval 109.  
 
Although the studies described above included detailed descriptions of the kinetics of drug interactions 
with ion channels, it is important to note that even detailed kinetic models are phenomenological - for 
example, a Markov model of ion channel dynamics or drug channel interactions is a phenomenological 
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representation that greatly simplifies the underlying molecular quantum mechanics.   In the studies 
described above, there is no way for example to predictively link atomic scale anomalies to higher 
order phenomenon, or to predict how structural perturbations might affect pharmacological effects in 
the whole heart.    An important aspect of modeling and simulation as it relates to prediction of disease 
processes and pharmacology is choosing the level of detail in the model.    There must be a match 
between the required complexity of the model and its predictive capacity, so as not to introduce 
unnecessary degrees of freedom that result in vastly over determined models. In other words, the 
modeler must be concerned with the issue of determining how to make the model "as simple as 
possible, but not simpler." 
 
Stem cells for predictive pharmacology 
The potential for personalized medicine via drug screening in patients’ own induced pluripotent stem 
(hiPSC) cell-derived cardiomyocytes (hiPSC-CMs) 110 is another developing and exciting application 
at the interface of molecular and clinical information 111,112. Patient-specific hiPSC-CMs containing 
unknown genotype profiles, or with known polymorphisms and/or mutations in cardiac ion channels 
can be used to qualitatively and quantitatively assess variability in drug responses 69.  Thus far, iPSC-
CMs have been used to successfully model arrhythmic disorders, with excellent agreement between 
altered cardiac channel function and emergent electrophysiological phenotypes in the inherited long 
QT syndromes and catecholaminergic polymorphic ventricular tachycardia 112.   
 
Terrenoire et al. recently demonstrated the usefulness of such an approach in a study where they 
derived iPSCs from a long QT syndrome patient with complex genetics 113.  They identified a de novo 
mutation in the SCN5A (F1473C) gene encoding the NaV1.5, and a polymorphism (K897T) in 
KCNH2, the gene encoding hERG. Biophysics and molecular pharmacological analysis of ion 
channels expressed in iPSC-CMs demonstrated that the disease was primary consequence of the 
NaV1.5 defect and was not influenced by the KCNH2 polymorphism. The mutation resulted in a gain-
of-function in INaL, which resulted in delayed repolarization, a prolonged QT interval, and increased 
risk of arrhythmia.   They also found a uniquely steep fast rate- dependent reduction in INaL that 
especially facilitated pharmacological inhibition by the Na channel blocker mexiletine.  Of critical 
importance, the experiments revealed rate-dependent properties of ion currents and drug interactions 
that were unique to the patient’s iPSC-CMs, and that were corroborated in a successful patient 
treatment regimen.   This study is an example for the potential of iPSC-CMs approaches in developing 
patient-specific clinical regimens 113. 
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While the study described above focused on a gain of function perturbation in the Na channel, and its 
cellular level effects, iPSC-CMs can also be cultured in monolayer or grown on scaffolds to investigate 
patient specific metrics related to loss of Na channel function, especially conduction velocity.   For 
example, measurements of voltage wavefronts in monolayers of iPSC-CMs via optical mapping with 
has recently been deomonstrated 114. 
 
The potential for expansion of stem cell technologies in the cardiac therapeutic arena is vast 111,115.   
For example, these cells may prove extremely useful to reveal some of the most basic variations in 
drug responses that might include the influence of sex, polytherapy, hormones, of course drug effects 
in the context of genetically based diseases.  Examples include the apparent differential effects of 
hERG blockade in males and females, oral contraceptive effects on cardiac risk, or to determine the 
electrophysiological effects of beta-blockers in LQT-3 patients 116 117 118.  In order for stem cells 
technologies to enter the mainstream for screening and therapy, best practices are in development to 




Understanding how disruption in cardiac Na+-based processes leads to derangement in multiple cardiac 
components at the level of the cell and to then connect these perturbation to emergent behavior in the 
heart to cause is a critical area of research. The ubiquity of disruption of sodium channels and sodium 
homeostasis in cardiac disorders of excitability and mechanics emphasizes the importance of 
fundamental understanding of the associated mechanisms and disease processes to ultimately reveal 
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